Paxman (Q3 Initial take): Slight sales miss, but solid underlying development - Redeye
Bildkälla: Stockfoto

Paxman (Q3 Initial take): Slight sales miss, but solid underlying development - Redeye

Redeye provides an initial take following Paxman’s Q3 2026 report. Sales came in 4% below our expectations, mainly due to weaker RoW sales, which we know can be lumpy between quarters. Looking at the underlying figures, however, the business continues to develop in the right direction, with IBBM volumes reaching a new record and US installations and the order book remaining strong. OPEX came in below our estimate, resulting in EBITDA and EBIT slightly above our forecasts (somewhat boosted by capitalisation of development costs). Overall, we view the report as solid, but given the high expectations ahead of the report, we see a risk that the market focuses on the sequential sales decline. However, we argue a fairly flat share price development is justifiable today. We will shortly release a research update, in which we expect to make only minor adjustments to our estimates.

Redeye provides an initial take following Paxman’s Q3 2026 report. Sales came in 4% below our expectations, mainly due to weaker RoW sales, which we know can be lumpy between quarters. Looking at the underlying figures, however, the business continues to develop in the right direction, with IBBM volumes reaching a new record and US installations and the order book remaining strong. OPEX came in below our estimate, resulting in EBITDA and EBIT slightly above our forecasts (somewhat boosted by capitalisation of development costs). Overall, we view the report as solid, but given the high expectations ahead of the report, we see a risk that the market focuses on the sequential sales decline. However, we argue a fairly flat share price development is justifiable today. We will shortly release a research update, in which we expect to make only minor adjustments to our estimates.
Börsvärldens nyhetsbrev